doctor head
 
  pharmacy and drugs  
search Search
 
       About us       News      A-Z Drugs      Stores      Top Drugs      Contact  
  doctor doctor hand
 
  doctor legs  
 
 
 
 

  Diseases

  Newsletter
Subscribe to our newsletter:
Name:
E-mail:
    Search results
Search results for: azine

1 - 5 of 25 <<previous | next>>

Drugs results:

Levitra tablets

Levitra

Levitra is one of a group of medicines that delay enzymes called phosphodiesterases from working too quickly, and is used to treat men who have erectile dysfunction. By controlling these enzymes, Levitra helps men maintain an erection. Levitra is also more...

Sibutramine pills

Sibutramine

Sibutramine is an anti-obesity agent. It affects chemicals in the body that are related to weight maintenance. Indication: for treatment of obesity as short-term supplement to diet and exercise Special precautions: Do not take sibutramine more...

Viagra tablets

Viagra

Sildenafil, also known as Viagra is one of a group of medicines that delay enzymes called phosphodiesterases from working too quickly, and is used to treat men who have erectile dysfunction. By controlling these enzymes Viagra helps men maintain an ere more...

Bontril tablets

Bontril

Often called Phendimetrazine, Bontril is a Sympathomimetic Appetite Suppressants used in the short-term treatment of obesity. Since their appetite-reducing effect tends to decrease after a few weeks, these medicines are useful only during the first few we more...

Levaquin tablets

Levaquin

Levaquin, or Levofloxacin, belongs to the class of medicines known as antibiotics. It is used to treat bacterial infections in many different parts of the body. Levaquin is also used to treat anthrax. Levaquin works by killing bacteria or preventing their more...

Diseases results:

Erectile dysfunction
Obesity
Bacterial infection
Weight loss
Schizophrenia
Gout
Proctitis
Ulcerative colitis

Articles results:

Spending On Prescription Drug Ads Increased By 9% In First Half Of 2006
Pharmaceutical companies increased spending on advertisements by 9% in the first half of 2006, an indication that they "no longer feel constrained" by criticism that their "splashy campaigns minimized medicines' risks" after the September 2004 withdrawal of the COX-2 inhibitor Vioxx, AP/Long Island Newsday reports. According to


Biotechs Expand Into Small Molecules For Drug Discovery
Biotech companies traditionally focus on large proteins in their quest to find new drugs. But faced with the complex nature of disease, these companies are increasingly turning to small molecules as well. This new push into small-molecule drug design, which researchers hope will deliver better and more effective disease treatments, is explored in a report scheduled for the Oct. 30 issue of Chemical & Engineering News, the ACS's weekly newsmagazine.Associate Editor Lisa M.


Long Island Newsday Examines American Medical Association Recommendations On Regulation Of Prescription Drug Advertisements
Long Island Newsday on Tuesday examined American Medical Association recommendations on regulation of direct-to-consumer prescription drug advertisements, which have become "ubiquitous" on television, radio, the Internet, and in newspapers and magazines (Mitchell, Long Island Newsday, 10/31).


Food And Drug Law Institute Sponsors National Colloquium On Access To Unapproved Drugs
Should terminally ill patients be allowed access to drugs not approved by the Food and Drug Administration? That is the question a panel of experts will discuss and debate at a landmark Colloquium, Whose Life Is It, Anyway?, sponsored by the Food and Drug Law Institute (FDLI), Feb. 27, 2007, in Washington, D.C. This meeting is the first in a series of colloquia to be sponsored by FDLI in upcoming months.


How Do You Measure Innovation In Pharmaceutical Industry? New Benchmarking Studies By Pharmaceutical Manufacturing And APQC
Drug development is a tremendous challenge for most pharmaceutical companies today. To launch any new drug, investments of $1 billion and 10 years are common, and, all too often, promising candidates fail to become manufacturable and marketable therapies. Efforts such as the Critical Path initiative, supported by the U.S. Food and Drug Administration (FDA), are underway to improve results.




1 - 5 of 25 <<previous | next>>

© 2006-2010 pharmacy-and-drugs.com. All rights reserved.